Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Furosemide + amiloride is a **combination drug** containing the loop diuretic furosemide and the potassium-sparing diuretic amiloride. This dual therapy is used primarily for the treatment of **hypertension (high blood pressure)** and **oedema (fluid retention)**, particularly when potassium conservation is important, such as in heart failure, liver disease, or nephrotic syndrome[1][3][7][9]. - **Furosemide** acts by inhibiting the sodium-potassium-chloride cotransporter (NKCC2) in the thick ascending loop of Henle, which blocks reabsorption of sodium and chloride and promotes diuresis[5]. - **Amiloride** inhibits epithelial sodium channels (ENaC) in the distal nephron, leading to reduced sodium reabsorption and conservation of potassium[2][6][8]. The combination is designed to clear excess fluid while counteracting furosemide-induced potassium loss[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on furosemide + amiloride.